Here's a number worth sitting with: SpaceX needed four attempts before a rocket it built reached orbit for the first time. Skyroot Aerospace, a startup most people outside India have never heard of, did it on the first try.
Skyroot's Vikram-1 rocket lifted off from Sriharikota Island on India's southeast coast early Saturday morning and climbed cleanly into a 280-mile-high orbit. The achievement makes it the first privately developed orbital rocket in Indian history — a milestone that felt, by the CEO's own admission, almost too good to be real.
"I never thought it was possible," said Pawan Kumar Chandana, Skyroot's cofounder and chief executive, addressing his team after the launch. That's not false modesty. First-attempt orbital success is genuinely rare in this business, and the list of companies that have pulled it off is very short.
The rocket itself is a modest machine — about 72 feet tall, capable of hauling roughly 770 pounds into low-Earth orbit. That puts it in the same weight class as Rocket Lab's Electron, currently the most active dedicated small-satellite launcher on the planet. Vikram-1 isn't trying to compete with the heavy-lift giants. It's chasing the growing market for smaller, cheaper, faster access to orbit, and Saturday's launch is a serious opening argument.
The flight used three solid-fueled stages stacked in sequence, followed by a liquid-fueled fourth stage to push the vehicle to orbital velocity — somewhere around 17,000 miles per hour. Cameras mounted on the rocket captured each stage separation live, giving viewers a front-row seat to the whole sequence. There was one slightly awkward moment when the spent third stage appeared to linger near the fourth stage a little longer than expected after separation, but it didn't cause any real trouble. The fourth stage fired its 3D-printed engine without issue and delivered the payload to the target orbit almost exactly as planned.
US military tracking data independently confirmed the rocket made it. When the Pentagon's radar tells you your rocket is in orbit, the argument is pretty much over.
This matters beyond the obvious national pride angle. India's government has been deliberately opening its space sector to private players over the past few years, and Skyroot has been one of the most closely watched bets in that experiment. A successful first launch doesn't just validate one company — it sends a signal to every engineer and investor in the country that building commercial rockets in India is not a fantasy.
For context, Rocket Lab's Electron failed to reach orbit on its first flight in 2017. Blue Origin's New Glenn succeeded on debut last year, but that team had years of suborbital launch experience behind them. Skyroot had neither that luxury nor that safety net, which makes Saturday's outcome all the more striking.
The small-satellite launch market is genuinely competitive right now, with players across the US, Europe, and Asia all fighting for the same contracts. Vikram-1's debut puts India's private sector on that map in a way that a near-miss never would have.
AI
AI Is Now Making Health Insurance Decisions in Government Pilot
Six states are currently running a government pilot program that uses artificial intelligence to decide whether your health insurance claim gets approved. If that sentence made your stomach drop a little, you are not alone — and you are in good company with roughly 61 percent of American physicians.
The program targets prior authorization, the process where insurers require doctors to get pre-approval before patients can receive certain treatments, medications, or procedures. In theory, it exists to prevent unnecessary spending. In practice, it has become one of the most despised administrative rituals in American medicine, responsible for treatment delays, abandoned care, and a staggering amount of paperwork that falls mostly on physicians and their staff.
The Trump administration's argument for introducing AI into this system is straightforward: if a machine can instantly scan a claim, match it against clinical guidelines, and approve the obvious ones without human delay, patients get faster care. That logic is not entirely wrong. The prior authorization backlog is real, and some claims that should sail through get stuck in the queue for days.
The problem is what happens when the algorithm is wrong — or worse, when it's optimized in ways that favor the insurer over the patient.
A 2025 survey by the American Medical Association found that nearly two-thirds of doctors are worried AI will make denial rates worse, not better. Their concern isn't hypothetical. Medicare Advantage plans — the privately administered alternative to traditional Medicare that now covers more than half of eligible seniors — already issue millions of full or partial denials every year. Federal reports released this past June showed that some plans are rejecting requests for skilled nursing and rehabilitation care, which is exactly the kind of decision that can derail a patient's recovery with almost no recourse.
Patients can appeal, of course. But the appeals process is complicated, slow, and often outlasts the window when treatment would actually have helped. NBC News has reported on patients trapped in prior authorization limbo until they simply run out of time or treatment options. Adding AI to that system doesn't automatically fix any of those structural problems — it just makes the decisions faster, for better or worse.
Health policy analyst Camm Epstein framed the core tension cleanly: AI should be used to make appropriate care easier to approve, not necessary care easier to deny. That distinction sounds obvious, but it's exactly the line that's genuinely hard to enforce when the entity running the algorithm has a financial interest in denial.
A Commonwealth Fund survey found that roughly one in five working-age American adults with private insurance reported having a claim denied or delayed in a way that affected their care. That's already a serious problem before you introduce a system that can process rejections at machine speed.
The pilot is still early, and the outcome is genuinely uncertain. AI could streamline a broken process. It could also industrialize its worst tendencies. The difference will depend almost entirely on how the technology is deployed — and who it's ultimately designed to serve.
Source: Ars Technica
The program targets prior authorization, the process where insurers require doctors to get pre-approval before patients can receive certain treatments, medications, or procedures. In theory, it exists to prevent unnecessary spending. In practice, it has become one of the most despised administrative rituals in American medicine, responsible for treatment delays, abandoned care, and a staggering amount of paperwork that falls mostly on physicians and their staff.
The Trump administration's argument for introducing AI into this system is straightforward: if a machine can instantly scan a claim, match it against clinical guidelines, and approve the obvious ones without human delay, patients get faster care. That logic is not entirely wrong. The prior authorization backlog is real, and some claims that should sail through get stuck in the queue for days.
The problem is what happens when the algorithm is wrong — or worse, when it's optimized in ways that favor the insurer over the patient.
A 2025 survey by the American Medical Association found that nearly two-thirds of doctors are worried AI will make denial rates worse, not better. Their concern isn't hypothetical. Medicare Advantage plans — the privately administered alternative to traditional Medicare that now covers more than half of eligible seniors — already issue millions of full or partial denials every year. Federal reports released this past June showed that some plans are rejecting requests for skilled nursing and rehabilitation care, which is exactly the kind of decision that can derail a patient's recovery with almost no recourse.
Patients can appeal, of course. But the appeals process is complicated, slow, and often outlasts the window when treatment would actually have helped. NBC News has reported on patients trapped in prior authorization limbo until they simply run out of time or treatment options. Adding AI to that system doesn't automatically fix any of those structural problems — it just makes the decisions faster, for better or worse.
Health policy analyst Camm Epstein framed the core tension cleanly: AI should be used to make appropriate care easier to approve, not necessary care easier to deny. That distinction sounds obvious, but it's exactly the line that's genuinely hard to enforce when the entity running the algorithm has a financial interest in denial.
A Commonwealth Fund survey found that roughly one in five working-age American adults with private insurance reported having a claim denied or delayed in a way that affected their care. That's already a serious problem before you introduce a system that can process rejections at machine speed.
The pilot is still early, and the outcome is genuinely uncertain. AI could streamline a broken process. It could also industrialize its worst tendencies. The difference will depend almost entirely on how the technology is deployed — and who it's ultimately designed to serve.
Enjoyed this?
Get stories like this delivered every Tuesday — free.